Top

Published in:

01-02-2022 | Shingles | Clinical study

Tofacitinib increases risk of MACE and cancer versus TNF inhibitors

Published in: Reactions Weekly | Issue 1/2022

Excerpt

Treatment with tofacitinib in patients with rheumatoid arthritis (RA) increases the risks of major adverse cardiovascular events (MACE) and cancer compared with tumour necrosis factor (TNF) inhibitors, according to findings of a Prizer-funded study published in the New England Journal of Medicine. …

Ytterberg SR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. New England Journal of Medicine 386: 316-326, No. 4, 27 Jan 2022. Available from: URL: http://doi.org/10.1056/NEJMoa2109927

Title: Tofacitinib increases risk of MACE and cancer versus TNF inhibitors
Publication date: 01-02-2022
Publisher: Springer International Publishing
Keywords: Shingles
TNF-Inhibitors
Rheumatoid Arthritis
Skin Cancer
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-09795-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tofacitinib increases risk of MACE and cancer versus TNF inhibitors

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Enoxaparin-sodium/heparin

Rivoceranib

Nivolumab

Venlafaxine

Dexamethasone/nepafenac

Antiepileptic drugs/immune-globulin